Search

Your search keyword '"Genge, Angela"' showing total 19 results
Start Over Author "Genge, Angela" Publisher informa uk limited
19 results on '"Genge, Angela"'

4. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

Author

Shefner, Jeremy M., primary, Al-Chalabi, Ammar, additional, Andrews, Jinsy A., additional, Chio, Adriano, additional, De Carvalho, Mamede, additional, Cockroft, Bettina M., additional, Corcia, Philippe, additional, Couratier, Philippe, additional, Cudkowicz, Merit E., additional, Genge, Angela, additional, Hardiman, Orla, additional, Heiman-Patterson, Terry, additional, Henderson, Robert D., additional, Ingre, Caroline, additional, Jackson, Carlayne E., additional, Johnston, Wendy, additional, Lechtzin, Noah, additional, Ludolph, Albert, additional, Maragakis, Nicholas J., additional, Miller, Timothy M., additional, Mora Pardina, Jesus S., additional, Petri, Susanne, additional, Simmons, Zachary, additional, Van Den Berg, Leonard H., additional, Zinman, Lorne, additional, Kupfer, Stuart, additional, Malik, Fady I., additional, Meng, Lisa, additional, Simkins, Tyrell J., additional, Wei, Jenny, additional, Wolff, Andrew A., additional, and Rudnicki, Stacy A., additional

Published
2023
Full Text
View/download PDF

5. Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

Author

Gebrehiwet, Paulos, primary, Meng, Lisa, additional, Rudnicki, Stacy A., additional, Sarocco, Phil, additional, Wei, Jenny, additional, Wolff, Andrew A., additional, Butzner, Michael, additional, Chiò, Adriano, additional, Andrews, Jinsy A., additional, Genge, Angela, additional, Hughes, Dyfrig A., additional, Jackson, Carlayne E., additional, Lechtzin, Noah, additional, Miller, Timothy M., additional, and Shefner, Jeremy M., additional

Published
2023
Full Text
View/download PDF

7. MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial

Author

Gebrehiwet, Paulos, primary, Meng, Lisa, additional, Rudnicki, Stacy A., additional, Sarocco, Phil, additional, Wei, Jenny, additional, Wolff, Andrew A., additional, Chiò, Adriano, additional, Andrews, Jinsy A., additional, Genge, Angela, additional, Jackson, Carlayne E., additional, Lechtzin, Noah, additional, Miller, Timothy M., additional, and Shefner, Jeremy M., additional

Published
2022
Full Text
View/download PDF

8. CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS

Author

Picher-Martel, Vincent, primary, Magnussen, Claire, additional, Blais, Mathieu, additional, Bubela, Tania, additional, Das, Samir, additional, Dionne, Annie, additional, Evans, Alan C., additional, Genge, Angela, additional, Greiner, Russell, additional, Iturria-Medina, Yasser, additional, Johnston, Wendy, additional, Jones, Kelvin, additional, Kaneb, Hannah, additional, Karamchandani, Jason, additional, Moradipoor, Sara, additional, Robertson, Janice, additional, Rogaeva, Ekaterina, additional, Taylor, David M., additional, Vande Velde, Christine, additional, Yunusova, Yana, additional, Zinman, Lorne, additional, Kalra, Sanjay, additional, and Dupré, Nicolas, additional

Published
2022
Full Text
View/download PDF

9. Genetic testing for amyotrophic lateral sclerosis in Canada – an assessment of current practices

Author

Salmon, Kristiana, primary, Anoja, Nancy, additional, Breiner, Ari, additional, Chum, Marvin, additional, Dionne, Annie, additional, Dupré, Nicolas, additional, Fiander, Amanda, additional, Fok, Daniel, additional, Ghavanini, Amer, additional, Gosselin, Sylvie, additional, Izenberg, Aaron, additional, Johnston, Wendy, additional, Kalra, Sanjay, additional, Matte, Geneviève, additional, Melanson, Michel, additional, O’Connell, Colleen, additional, Ritsma, Benjamin, additional, Schellenberg, Kerri, additional, Shoesmith, Christen, additional, Tremblay, Sandra, additional, Williams, Heather, additional, and Genge, Angela, additional

Published
2021
Full Text
View/download PDF

10. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis

Author

Shefner, Jeremy M, Cudkowicz, Merit E, Hardiman, Orla, Cockroft, Bettina M, Lee, Jacqueline H, Malik, Fady, Meng, Lisa, Rudnicki, Stacy A, Wolff, Andrew A, Andrews, Jinsy A, Van Damme, Philip, Korngut, Lawrence, Johnston, Wendy, O'Connell, Colleen, Grant, Ian, Turnbull, John, Shoesmith, Christen, Zinman, Lorne, Botez, Stephan, Genge, Angela, Dionne, Annie, Couratier, Philippe, Attarian, Shahram, Pouget, Jean, Camu, William, Desnuelle, Claude, Salachas, Francois, Corcia, Philippe, Meyer, Thomas, Petri, Susanne, Ludolph, Albert, Calvo, Andrea, Lunetta, Christian, Silani, Vincenzo, van den Berg, Leonard, de Carvalho, Mamede, Mora Pardina, Jesus, Young, Carolyn, Al-Chalabi, Ammar, Radunovic, Aleksander, Hanemann, Clemens, Ladha, Shafeeq, Goyal, Namita, Ravits, John, Lewis, Richard, Joyce, Nanette, Oskarsson, Bjorn, Katz, Jonathan S, So, Yuen, Quan, Dianna, Felice, Kevin, Bayat, Elham, Boylan, Kevin, Benatar, Michael G, Tuan, Vu, Glass, Jonathan, Sufit, Robert, Bodkin, Cynthia, Swenson, Andrea, Statland, Jeffrey, Maragakis, Nicholas, Berry, James, Brown, Robert, Salameh, Johnny, Goutman, Stephen, Newman, Daniel S, Guliani, Gaurav, Maiser, Samuel, Pestronk, Alan, Hayat, Ghazala, Pattee, Gary, Cohen, Jeffrey, Brooks, Benjamin, Bedlack, Richard, Caress, James, Mitsumoto, Hiroshi, Lange, Dale, Bradshaw, Deborah, Kolb, Stephen J, Karam, Chafic, Khoury, Julie, Goslin, Kimberly, Simmons, Zachary, Mc Cluskey, Leo, Heiman-Patterson, Terry, Donofrio, Peter, Heitzman, Daragh, Harati, Yadollah, Jackson, Carlayne, Phillips, Lawrence, Weiss, Michael, Nance, Christopher, Sultan, Shumaila, Barkhaus, Paul, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Trinity College Dublin

Subjects
amyotrophic lateral sclerosis, medicine.medical_specialty, Tirasemtiv, tirasemtiv, [SDV]Life Sciences [q-bio], [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Clinical Neurology, Placebo, law.invention, ACTIVATION, DOUBLE-BLIND, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, In patient, Amyotrophic lateral sclerosis, Science & Technology, PLACEBO, biology, business.industry, Skeletal muscle, EFFICACY, medicine.disease, Troponin, Clinical trial, medicine.anatomical_structure, Neurology, SAFETY, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, biology.protein, Cardiology, Neurosciences & Neurology, Randomized clinical trial, Neurology (clinical), business, Life Sciences & Biomedicine, 030217 neurology & neurosurgery
Abstract

OBJECTIVE: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyotrophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, placebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting 28 days. The primary outcome measure was changed in slow vital capacity (SVC) at 24 weeks. Secondary endpoints included a change in muscle strength and time to respiratory milestones of disease progression. RESULTS: Of 744 participants, 565 tolerated open-label tirasemtiv and received randomized treatment. By 24 weeks, 23 (12.2%) placebo-treated participants discontinued study treatment vs. 129 (34.2%) randomized to tirasemtiv. SVC declined by 14.4% (95% CI: −16.8, −11.9) in the placebo group and 13.4% (95% CI: −15.3, −11.6) in the tirasemtiv group (p = 0.56). Secondary endpoints did not show significant differences. However, participants who tolerated tirasemtiv at their randomized dose showed a numeric trend toward a dose-related slowing of decline in SVC (p = 0.11). Dizziness, fatigue, nausea, weight loss, and insomnia occurred more frequently on tirasemtiv. Serious adverse events were similar across groups. CONCLUSIONS: Tirasemtiv did not alter the decline of SVC or significantly impact secondary outcome measures. Poor tolerability of tirasemtiv may have contributed to this result. However, participants tolerating their intended dose exhibited a trend toward treatment benefit on SVC, suggesting the underlying mechanism of action may still hold promise, as is being tested with a different fast skeletal muscle troponin activator (NCT03160898). ispartof: AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION vol:20 issue:7-8 pages:584-594 ispartof: location:England status: published

Published
2019

11. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Author

Shefner, Jeremy M., primary, Andrews, Jinsy A., additional, Genge, Angela, additional, Jackson, Carlayne, additional, Lechtzin, Noah, additional, Miller, Timothy M., additional, Cockroft, Bettina M., additional, Meng, Lisa, additional, Wei, Jenny, additional, Wolff, Andrew A., additional, Malik, Fady I., additional, Bodkin, Cynthia, additional, Brooks, Benjamin R., additional, Caress, James, additional, Dionne, Annie, additional, Fee, Dominic, additional, Goutman, Stephen A., additional, Goyal, Namita A., additional, Hardiman, Orla, additional, Hayat, Ghazala, additional, Heiman-Patterson, Terry, additional, Heitzman, Daragh, additional, Henderson, Robert D., additional, Johnston, Wendy, additional, Karam, Chafic, additional, Kiernan, Matthew C., additional, Kolb, Stephen J., additional, Korngut, Lawrence, additional, Ladha, Shafeeq, additional, Matte, Genevieve, additional, Mora, Jesus S., additional, Needham, Merrilee, additional, Oskarsson, Bjorn, additional, Pattee, Gary L., additional, Pioro, Erik P., additional, Pulley, Michael, additional, Quan, Dianna, additional, Rezania, Kourosh, additional, Schellenberg, Kerri L., additional, Schultz, David, additional, Shoesmith, Christen, additional, Simmons, Zachary, additional, Statland, Jeffrey, additional, Sultan, Shumaila, additional, Swenson, Andrea, additional, Berg, Leonard H. Van Den, additional, Vu, Tuan, additional, Vucic, Steve, additional, Weiss, Michael, additional, Whyte-Rayson, Ashley, additional, Wymer, James, additional, Zinman, Lorne, additional, and Rudnicki, Stacy A., additional

Published
2020
Full Text
View/download PDF

12. Reliability and validity of speech & pause measures during passage reading in ALS

Author

Barnett, Carolina, primary, Green, Jordan R., additional, Marzouqah, Reeman, additional, Stipancic, Kaila L., additional, Berry, James D., additional, Korngut, Lawrence, additional, Genge, Angela, additional, Shoesmith, Christen, additional, Briemberg, Hannah, additional, Abrahao, Agessandro, additional, Kalra, Sanjay, additional, Zinman, Lorne, additional, and Yunusova, Yana, additional

Published
2019
Full Text
View/download PDF

14. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Author

Mora, Jesús S., Genge, Angela, Chio, Adriano, Estol, Conrado J., Chaverri, Delia, Hernández, María, Marín, Saúl, Mascias, Javier, Rodríguez, Gabriel E., Povedano, Mònica, Paipa, Andres Julian, Domínguez, Raúl, Gamez, Josep, Salvado, Maria, Lunetta, Christian, Ballario, Carlos, Riva, Nilo, Mandrioli, Jessica, Moussy, Alain, Kinet, Jean-Pierre, Auclair, Christian, Dubreuil, Patrice, Arnold, Vincent, Mansfield, Colin D., Hermine, Olivier, The Ab10015 Study Group, Montreal Neurological Institute and Hospital, McGill University = Université McGill [Montréal, Canada], Università degli studi di Torino (UNITO), Neurological Center for Treatment and Research, Universidade da Coruña, DFKI Bremen (DFKI), Deutsches Forschungszentrum für Künstliche Intelligenz GmbH = German Research Center for Artificial Intelligence (DFKI), Vall d'Hebron University Hospital [Barcelona], AB Science, Harvard Medical School [Boston] (HMS), Laboratoire de biologie et pharmacologie appliquée (LBPA), Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Ecole Normale Supérieure Paris-Saclay (ENS Paris Saclay), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Università degli studi di Torino = University of Turin (UNITO), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Oncology, Pyridines, [SDV]Life Sciences [q-bio], Tyrosine kinase inhibitor, masitinib, Tyrosine-kinase inhibitor, law.invention, chemistry.chemical_compound, tyrosine kinase inhibitor, 0302 clinical medicine, Clinical trials, Piperidines, Randomized controlled trial, law, Protein kinases, therapy, Young adult, Amyotrophic lateral sclerosis, Riluzole, Masitinib, Middle Aged, 3. Good health, Treatment Outcome, Neurology, Benzamides, Disease Progression, Female, medicine.drug, Adult, medicine.medical_specialty, Adolescent, medicine.drug_class, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Therapeutics, Placebo, Young Adult, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Aged, Amyotrophic Lateral Sclerosis, Humans, Thiazoles, business.industry, medicine.disease, Terapèutica, Clinical trial, Proteïnes quinases, chemistry, Therapy, Neurology (clinical), business, 030217 neurology & neurosurgery, Assaigs clínics
Abstract

Financial support for medical editorial assistance was provided by AB Science. We thank the study participants, their families, and caregivers. We also thank the AB10015 Study Group collaborators (Supplementary eTable 1). The Spanish ALS Research Foundation, FUNDELA, contributed to Dr. Mora's group support. Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assigning 394 patients (1:1:1) to receive riluzole (100 mg/d) plus placebo or masitinib at 4.5 or 3.0 mg/kg/d. Following a blinded transition from phase 2 to phase 2/3, a prospectively defined two-tiered design was implemented based on ALSFRS-R progression rate from disease-onset to baseline (ΔFS). This approach selects a more homogeneous primary efficacy population ("Normal Progressors", ΔFS < 1.1 points/month) while concurrently permitting secondary assessment of the broader population. Primary endpoint was decline in ALSFRS-R at week-48 (ΔALSFRS-R), with the high-dose "Normal Progressor" cohort being the prospectively declared primary efficacy population. Missing data were imputed via last observation carried forward (LOCF) methodology with sensitivity analyses performed to test robustness. Results: For the primary efficacy population, masitinib (n = 99) showed significant benefit over placebo (n = 102) with a ΔALSFRS-R between-group difference (ΔLSM) of 3.4 (95% CI 0.65-6.13; p = 0.016), corresponding to a 27% slowing in rate of functional decline (LOCF methodology). Sensitivity analyses were all convergent, including the conservative multiple imputation technique of FCS-REGPMM with a ΔLSM of 3.4 (95% CI 0.53-6.33; p = 0.020). Secondary endpoints (ALSAQ-40, FVC, and time-to-event analysis) were also significant. Conversely, no significant treatment-effect according to ΔALSFRS-R was seen for the broader "Normal and Fast Progressor" masitinib 4.5 mg/kg/d cohort, or either of the low-dose (masitinib 3.0 mg/kg/d) cohorts. Rates of treatment-emergent adverse events (AEs) (regardless of causality or post-onset ΔFS) were 88% with masitinib 4.5 mg/kg/d, 85% with 3.0 mg/kg/d, and 79% with placebo. Likewise, rates of serious AE were 31, 23, and 18%, respectively. No distinct event contributed to the higher rate observed for masitinib and no deaths were related to masitinib. Conclusions: Results show that masitinib at 4.5 mg/kg/d can benefit patients with ALS. A confirmatory phase 3 study will be initiated to substantiate these data.

Published
2019

17. Understanding the use of NIV in ALS: results of an international ALS specialist survey

Author

Heiman-Patterson, Terry D., primary, Cudkowicz, Merit E., additional, De Carvalho, Mamede, additional, Genge, Angela, additional, Hardiman, Orla, additional, Jackson, Carlayne E., additional, Lechtzin, Noah, additional, Mitsumoto, Hiroshi, additional, Silani, Vincenzo, additional, Andrews, Jinsy A., additional, Chen, Dafeng, additional, Kulke, Sarah, additional, Rudnicki, Stacy A., additional, and van den Berg, Leonard H., additional

Published
2018
Full Text
View/download PDF

18. Respiratory measures in amyotrophic lateral sclerosis

Author

Lechtzin, Noah, primary, Cudkowicz, Merit E., additional, de Carvalho, Mamede, additional, Genge, Angela, additional, Hardiman, Orla, additional, Mitsumoto, Hiroshi, additional, Mora, Jesus S., additional, Shefner, Jeremy, additional, Van den Berg, Leonard H., additional, and Andrews, Jinsy A., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results